Innomar's Role In Addressing A Critical Drug Shortage

When manufacturing delays triggered a critical shortage of a specialty drug product in Canada, the window to protect patient access was narrow, and the regulatory, logistical, and operational hurdles were significant. The manufacturer needed a partner who could move fast without cutting corners: securing a DEL amendment, navigating exceptional importation requirements, coordinating cross-border logistics, and standing up a patient support program, all on a compressed timeline.

What made the difference wasn't just capability. It was the trust already built between Innomar, the client, and Health Canada that allowed each workstream to accelerate in parallel. The DEL amendment was approved in 30 days. Full distribution and PSP readiness was achieved within three months with zero patient impact. This case study shows what integrated service delivery looks like when the stakes are highest. Read the full story to see how it came together.